Skip to content

Retrospective Study of Adult Patients With Inborn Errors of Metabolism in Switzerland

Clinical Characteristics of Adult Patients With Inborn Errors of Metabolism in French-speaking Switzerland

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03534752
Enrollment
220
Registered
2018-05-23
Start date
2018-04-01
Completion date
2020-04-01
Last updated
2021-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inborn Errors of Metabolism

Keywords

Inborn errors of Metabolism, Adulthood, Clinical characteristics

Brief summary

This is a retrospective study aimed at establishing a database of the current health of adult patients with IEM in the French-speaking part of Switzerland. .

Detailed description

Background Inborn errors of metabolism (IEMs) are a group of rare disorders caused by genetic mutations that affect enzymes of intermediary metabolism. Because adult with IEMs has become an emerging and challenging group in Switzerland, this study is intended to assess the actual situation of adult patients with IEM in the French-speaking part of Switzerland, namely their age, their sex, their diagnosis, age at disease onset and their clinical outcome including complications of the disease. All adult patients with a biochemical and/or genetic diagnosis of IEM followed at the adult metabolic clinic from the Lausanne University Hospital and Geneva University Hospital between 01.10.2013 to 31.12.2017 will be included in the study. In addition, investigators will also include the patients referred to the clinic for suspicion of IEM and determinate if the investigation confirmed an IEM disease. Electronic and paper patient charts will be reviewed for clinical features, biochemical investigations, molecular genetic testing, diagnostic imaging, treatment and long-term outcome. All data will be entered in an Excel database.

Interventions

None listed

Sponsors

University of Lausanne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All IEM adult patients who were transitioned from the pediatric clinic to the adult metabolic clinic (the Centre for Molecular Disease in Lausanne and the Division of Endocrinology, Diabetology, Hypertension and Nutrition of the HUG) since its creation in 2013 and those who were referred to our clinic for suspicion of IEM and requiring further investigation.

Exclusion criteria

* Age \< 16 years . Any document attesting a refusal to participate will exclude the data entry of the concerned patient.

Design outcomes

Primary

MeasureTime frameDescription
Survival rate (%)4 yearsClinical Outcome
Gender (Male/female)First visitDemography outcome
Specific diagnosis of IEM listed by their frequencyFirst visitClinical outcome
Age at diagnosis (years/months)First visitClinical outcome
Medical complications4 yearsClinical outcome including acute liver failure, nephropathy, metabolic acidosis, ophthalmologic anomalies, epilepsy, encephalopathy, myopathy, neuropathy, diabetes
Specific treatment for Inborn Errors of Metabolism4 yearsTreatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, carnitine, ubiquinone, vitamins, specific diet, dialysis, specific metabolic formula
Number of hospital admission4 yearsClinical outcome

Secondary

MeasureTime frameDescription
Molecular analysis results of candidate gene for Inborn Errors of metabolism4 yearsLaboratory including mutation results confirming the molecular origin of the disease when available
Enzyme activity in leucocytes and/or fibroblasts4 yearsEnzyme activity of deficient enzyme when available for lysosomal storage diseases, mucopolysaccharidoses, cobalamin deficiency, diseases, classical homocystinuria
Abdominal Ultrasound results4 yearsRadiological Imaging description of spleen and/or liver when available (size, echostructure)
Magnetic resonance Imaging scan4 yearsRadiological Imaging description of brain, abdomen and bone when available
Bone density test4 yearsRadiological Imaging description of bone including T-score when available
Biological biomarkers of specific diseases (lysosomal storage disorders and galactosemia)4 yearsLaboratory including blood concentration of chitotriosidase and Galactose-1-Phosphate
Clinical chemistry4 yearsLaboratory including blood concentration of sodium, potassium, liver function tests, creatinine, uric acid, urea, amino acids, acylcarnitine profile, methylmalonate, total homocysteine and urine concentration of organic acids
Hematology tests4 yearsLaboratory (blood count, international normalized ratio, prothrombin time)

Other

MeasureTime frameDescription
Educational level4 yearsDemography outcome
Profession4 yearsDemography outcome

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026